X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES SUN PHARMA ALKEM LABORATORIES/
SUN PHARMA
 
P/E (TTM) x - 45.9 - View Chart
P/BV x 6.7 3.7 180.5% View Chart
Dividend Yield % 0.6 0.6 104.5%  

Financials

 ALKEM LABORATORIES   SUN PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
SUN PHARMA
Mar-17
ALKEM LABORATORIES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,589842 188.7%   
Low Rs1,232572 215.2%   
Sales per share (Unadj.) Rs417.5131.6 317.2%  
Earnings per share (Unadj.) Rs56.332.7 172.1%  
Cash flow per share (Unadj.) Rs64.738.0 170.4%  
Dividends per share (Unadj.) Rs12.703.50 362.9%  
Dividend yield (eoy) %0.90.5 181.9%  
Book value per share (Unadj.) Rs292.9152.7 191.8%  
Shares outstanding (eoy) m119.572,399.26 5.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.45.4 62.9%   
Avg P/E ratio x25.121.6 115.9%  
P/CF ratio (eoy) x21.818.6 117.0%  
Price / Book Value ratio x4.84.6 104.0%  
Dividend payout %22.610.7 210.8%   
Avg Mkt Cap Rs m168,6531,696,877 9.9%   
No. of employees `000NA17.5 0.0%   
Total wages/salary Rs m9,17149,023 18.7%   
Avg. sales/employee Rs ThNM18,028.3-  
Avg. wages/employee Rs ThNM2,798.8-  
Avg. net profit/employee Rs ThNM4,479.5-  
INCOME DATA
Net Sales Rs m49,915315,784 15.8%  
Other income Rs m1,6456,232 26.4%   
Total revenues Rs m51,561322,016 16.0%   
Gross profit Rs m8,482100,893 8.4%  
Depreciation Rs m1,00612,648 8.0%   
Interest Rs m6713,998 16.8%   
Profit before tax Rs m8,45190,479 9.3%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,60612,116 13.3%   
Profit after tax Rs m6,73178,462 8.6%  
Gross profit margin %17.031.9 53.2%  
Effective tax rate %19.013.4 141.9%   
Net profit margin %13.524.8 54.3%  
BALANCE SHEET DATA
Current assets Rs m27,062329,537 8.2%   
Current liabilities Rs m15,324178,870 8.6%   
Net working cap to sales %23.547.7 49.3%  
Current ratio x1.81.8 95.9%  
Inventory Days Days6779 84.2%  
Debtors Days Days4183 49.6%  
Net fixed assets Rs m12,610204,766 6.2%   
Share capital Rs m2392,399 10.0%   
"Free" reserves Rs m34,490363,997 9.5%   
Net worth Rs m35,027366,397 9.6%   
Long term debt Rs m1,21214,361 8.4%   
Total assets Rs m54,387614,102 8.9%  
Interest coverage x13.623.6 57.6%   
Debt to equity ratio x00 88.3%  
Sales to assets ratio x0.90.5 178.5%   
Return on assets %13.613.4 101.4%  
Return on equity %19.221.4 89.7%  
Return on capital %24.924.8 100.1%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56344,118 14.9%   
Fx outflow Rs m3,01224,484 12.3%   
Net fx Rs m3,55219,634 18.1%   
CASH FLOW
From Operations Rs m7,25970,822 10.2%  
From Investments Rs m1,864-42,216 -4.4%  
From Financial Activity Rs m-9,273-22,854 40.6%  
Net Cashflow Rs m-1506,107 -2.5%  

Share Holding

Indian Promoters % 66.9 63.7 105.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 5.1 645.2%  
FIIs % 0.0 23.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 8.3 -  
Shareholders   68,381 133,026 51.4%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   BIOCON LTD  CADILA HEALTHCARE  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Rising Oil Prices; RBI Minutes and Top Stocks in Action Today(Pre-Open)

Indian share markets surged on Wednesday, snapping a two-day losing streak led by gains Reliance Industries and bank stocks.

Related Views on News

SUN PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 12.0%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, SUN PHARMA has posted a net profit of Rs 16 bn (up 12.0% YoY). Sales on the other hand came in at Rs 70 bn (down 2.2% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jun 20, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS